

Outbreak of vancomycin-resistant *Enterococcus* in a renal transplant unit

Dear Editor,

In hemodialysis units, vancomycin-resistant *Enterococcus* (VRE) colonization is common, probably associated with vancomycin use and the characteristics of these patients. This panorama of colonization is also found in renal transplant units (RTU).¹ However, epidemiological data including risk factors associated with colonization or infection due to VRE in this population are scanty. Here, we describe an outbreak and the measures used to eradicate VRE in a RTU.

The outbreak took place in a RTU of a 700-bed University Hospital in Curitiba (PR, Brazil). The first case of VRE in this hospital was described in 2004 and the percentage of VRE infection has been between 1.16% and 2.4%.

In March 1, 2009 the first case of VRE in the RTU was reported. Thus, three samples of rectal swabs were obtained from all patients admitted to the unit. Three patients turned out positive and one patient was negative in the first day. In the second week, two cases of VRE colonization were found and one patient had a negative culture. In the third week, one of eight patients was positive. In the fourth week one out of six patients was positive. Since then, no other patient with VRE was found in the RTU. Surveillance was discontinued after four months of continuous vigilance. During the outbreak, a total of eight patients were found to be colonized and one patient was infected (urinary tract infection) from a total of 33 patients screened in the unit. Environmental samples, such as beds, clothes, walls, tables, chairs, doors, doorknobs, stretcher, mattresses, pillows, and several other objects were all negative. Cultures from the hands of healthcare workers were also negative.

Vancomycin resistance was confirmed using Kirby-Bauer disk diffusion and the E-test.²

PCR to detect VRE resistance genes was performed following Petrich et al.,³ which amplified the *vanA* gene in all strains of

Enterococcus faecium. Pulsed-field electrophoresis, described elsewhere, demonstrated a predominant genotype.⁴ Genotype A and its subtype A1 were found in the RTU, and genotype B was found in patients from other units.

A case-control study was performed. Cases included all VRE colonized/infected patients from the RTU. Controls were patients with three rectal swabs negative for VRE admitted during the same period (four months) to the unit. Clinical data were extracted from the medical records and are described in the Table 1. Duration of hospitalization and previous use of ceftriaxone were risk factors for VRE in the univariate analysis. Ceftriaxone was an isolated risk factor for VRE in the binary regression ($p = 0.029$), demonstrating an OR = 8.8 (95% CI: 1.25-62.20).

An educational program about VRE was implemented following published guidelines.⁵ The major focus of the education program was to enforce healthcare workers to adhere to contact isolation guidelines: I) wear of gown; II) use of gloves; III) hand hygiene using alcohol gel before and after any patient manipulation. Daily bath with chlorhexidine was done for all patients as an additional measure to control the outbreak. All material (clothes, pillows etc) used by patients were separated in plastic bags to further sterilization (autoclave or ethylene oxide).

Previous use of third generation cephalosporins was the only independent risk factor for VRE colonization in this outbreak. Although vancomycin has always been described as risk factor for VRE, third generation cephalosporins have also been nailed down in small series.^{6,7}

Costs related to VRE infection can exceed three times the average admission.⁸ In addition to extra cost, there is the risk of developing of an endemic status of VRE. In our study, intensive measures were effective to control the outbreak. The

Authors

Felipe Francisco Tuon¹
Sergio Ricardo Pentead-Filho²
Janaina Camilotti³
Inneke Marie van der Heijden⁴
Silvia Figueiredo Costa⁵

¹MD, PhD; Professor, Division of Infectious and Parasitic Diseases, Hospital Universitário Evangélico de Curitiba, Curitiba, PR, Brazil

²MD; Division of Infectious and Parasitic Diseases, Hospital Universitário Evangélico de Curitiba, Curitiba, PR, Brazil

³MPharm, Hospital Universitário Evangélico de Curitiba, Curitiba, PR, Brazil

⁴PhD, Department of Infectious Diseases and LIM-54, Universidade de São Paulo, SP, Brazil

⁵MD, PhD; Department of Infectious Diseases and LIM-54, Universidade de São Paulo, SP, Brazil

Submitted on: 11/25/2010

Approved on: 01/3/2011

Correspondence to:

Felipe Francisco Tuon
Infectious and Parasitic Diseases Clinic
Hospital Universitário Evangélico de Curitiba
Alameda Augusto
Stellfeld 1908,
3º andar – SCIH,
Bigorriho
80730-150
Curitiba, Brazil
flptuon@gmail.com

We declare no conflict of interest.

©2011 Elsevier Editora Ltda.
All rights reserved.

Table 1. Case control study of patients colonized/infected with VRE during an outbreak

Variable	VRE positive (n = 9)	VRE negative (n = 24)	p-value
Age (median with range)	36 (15 - 49)	37 (8 - 70)	NS
Gender (male %)	55.55%	58.33%	NS
Admission duration (mean ± SD)	16.11 ± 15.71	7.65 ± 3.90	0.018
DM	0.00%	4.16%	NS
ICC	11.11%	4.16%	NS
HAS	25.00%	33.33%	NS
Intensive care unit	0.00%	4.16%	NS
Surgery	11.11%	20.83%	NS
Neoplasm	0.00%	0.00%	NS
Under dialysis	11.11%	8.32%	NS
Cyclosporine	22.22%	20.83%	NS
Mophethyl-mycophenolate	100.00%	95.83%	NS
Tacrolimus	77.77%	54.13%	NS
Prednisone	100.00%	95.83%	NS
Azathioprine	0.00%	0.00%	NS
Urinary catheter	11.11%	29.16%	NS
Previous renal transplant	22.22%	4.16%	NS
Previous antibiotic use			
Ceftriaxone	44.44%	8.32%	0.034
Cefepime	11.11%	0.00%	NS
Carbapenem	0.00%	0.00%	NS
Piperacillin-tazobactam	0.00%	0.00%	NS
Vancomycin	22.22%	0.00%	0.068
Metronidazole	0.00%	0.00%	NS
Mortality	0%	4.10%	NS

NS, non-significant.

infection control activities to tackle the outbreak were extended to four months, a decision based on previous studies, which showed recurrence when carried out for only two months.^{9,10}

Adherence to all measures of isolation and use of alcohol gel are enough to control a VRE outbreak, including cohort in larger units.¹¹ Some authors demonstrated that even with all measures applied, VRE can become endemic in the hospital.¹² Guidelines are available but we believe that the most important in an outbreak is the continuous and intensive staff education.¹³

Daily chlorhexidine bathing decreases the incidence of colonization by Gram-positive cocci, but its use as a measure of control of VRE outbreak has not been described. Skin colonization is a major source of VRE and reduction in the VRE acquisition rate reduces the colonization pressure.¹⁴

This study contributes to the understanding of the epidemiology dynamics of a VRE outbreak in RTUs and highlights infection control measures that can be useful in the control of VRE spread.

REFERENCES

1. Freitas MC, Pacheco-Silva A, Barbosa D et al. Prevalence of vancomycin-resistant *Enterococcus* fecal colonization among kidney transplant patients. *BMC Infect Dis* 2006; 6:133.
2. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. Clinical and Laboratory Standards Institute. Fifteenth Informational Supplement. 2005. Pennsylvania, USA. Ref Type: Serial (Book, Monograph)

3. Petrich AK, Luinstra KE, Groves D et al. Direct detection of *vanA* and *vanB* genes in clinical specimens for rapid identification of vancomycin resistant enterococci (VRE) using multiplex PCR. *Mol Cell Probes* 1999; 13:275-81.
4. Tenover FC, Arbeit RD, Goering RV et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. *J Clin Microbiol* 1995; 33:2233-9.
5. Muto CA, Jernigan JA, Ostrowsky BE et al. SHEA Guideline for Preventing Nosocomial Transmission of Multidrug-Resistant Strains of *Staphylococcus aureus* and *Enterococcus*. *Infect Control Hosp Epidemiol* 2003; 24:362-86.
6. Carmeli Y, Eliopoulos GM, Samore MH. Antecedent treatment with different antibiotic agents as a risk factor for vancomycin-resistant *Enterococcus*. *Emerg Infect Dis* 2002; 8:802-7.
7. Askarian M, Afkhamzadeh R, Monabbati A et al. Risk factors for rectal colonization with vancomycin-resistant enterococci in Shiraz, Iran. *Int J Infect Dis* 2008; 12:171-5.
8. Muto CA, Giannetta ET, Durbin LJ et al. Cost-effectiveness of perirectal surveillance cultures for controlling vancomycin-resistant *Enterococcus*. *Infect Control Hosp Epidemiol* 2002; 23:429-35.
9. Aumeran C, Baud O, Lesens O et al. Successful control of a hospital-wide vancomycin-resistant *Enterococcus faecium* outbreak in France. *Eur J Clin Microbiol Infect Dis* 2008; 27(11):1061-4.
10. Schmidt-Hieber M, Blau IW, Schwartz S et al. Intensified strategies to control vancomycin-resistant enterococci in immunocompromised patients. *Int J Hematol* 2007; 86:158-62.
11. Ott M, Wirick H. Vancomycin-resistant enterococci (VRE) and the role of the healthcare worker. *Can Oper Room Nurs J* 2008 ;26:21-9,32.
12. Kurup A, Chlebicki MP, Ling ML et al. Control of a hospital-wide vancomycin-resistant enterococci outbreak. *Am J Infect Control* 2008; 36:206-11.
13. Peta M, Carretto E, Barbarini D et al. Outbreak of vancomycin-resistant *Enterococcus* spp. in an Italian general intensive care unit. *Clin Microbiol Infect* 2006; 12:163-9.
14. Vernon MO, Hayden MK, Trick WE et al. Chlorhexidine gluconate to cleanse patients in a medical intensive care unit: the effectiveness of source control to reduce the bioburden of vancomycin-resistant enterococci. *Arch Intern Med* 2006; 166:306-12.